secwatch.observer — SEC 8-K summary
======================================

Issuer:     BriaCell Therapeutics Corp. (BCTX)
CIK:        0001610820
Form:       8-K
Filed at:   2025-08-26T23:59:59+00:00
Accession:  0001641172-25-025438
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BriaCell Therapeutics announces 1-for-10 reverse stock split effective August 25, 2025 to maintain Nasdaq listing
--------------------------------------------------------------------------------

- Share consolidation of 1 post-split share for every 10 pre-split shares, effective August 25, 2025.
- Post-consolidation common shares trade on Nasdaq (BCTX) and TSX (BCT) under same symbols.
- Consolidation intended to ensure continued compliance with Nasdaq listing requirements.
- No fractional shares issued; fractions less than 0.5 cancelled, 0.5 or greater rounded up to one share.
- Outstanding convertible securities' exercise/conversion prices proportionately adjusted.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1610820/000164117225025438/0001641172-25-025438-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1610820/000164117225025438/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-025438

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer